CINCINNATI, Feb. 8 (Korea Bizwire) — Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the JetSeq™ DNA Library Preparation portfolio for Next Generation Sequencing (NGS) sample preparation.
Developed in collaboration with Oxford Gene Technology (OGT), the new JetSeq™ DNA Library Preparation Kits use pre-optimized buffers to provide maximum reaction efficiency and highest conversion rates, enabling the preparation of the highest quality NGS sequencing-ready, adapter-ligated DNA for Illumina’s Next Generation Sequencers. A combination of end repair and A-tailing followed by direct ligation of customer supplied adapters, reduces clean-up steps and hands-on time; significantly improving the yield and quality of sequence-ready libraries, reducing the amount of DNA required. The new kits are supplied either with polymerase, for PCR amplification with lower starting material, or PCR-free kit where starting material is not limited.
Marco Calzavara, President of Bioline commented, “The release of the new JetSeq™ DNA Library Preparation Kits compliments the JetSeq™ kit that we launched just over a year ago, moving Bioline further into the NGS space. The kits build on our extensive knowledge in the creation of highly efficient enzymes and buffer formulation and give our customers even more choice in library preparation, allowing them to tackle even the most challenging samples with confidence, in this very fast moving field.”
Richard L. Eberly, President, Chief Commercial Officer, stated, “We are excited about the release of the new JetSeq™ DNA Library Preparation Kits. This enhances our portfolio and gives a greater choice to our life science customers; allowing faster preparation, reducing time to results, and increases throughput. The development of the JetSeq™ family shows our commitment, not just to the continued development and expansion of products from Bioline, but also to our customers, giving them a greater choice of these high quality reagents.”
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
For Additional information:
For more information about Bioline, please visit http://www.bioline.com.
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Source: Meridian Bioscience, Inc. via GLOBE NEWSWIRE